Werewolf Therapeutics, Inc. (HOWL)
| Market Cap | 47.92M -32.8% |
| Revenue (ttm) | 21.00M |
| Net Income | -34.61M |
| EPS | -0.75 |
| Shares Out | 48.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 415,476 |
| Open | 1.0900 |
| Previous Close | 1.1000 |
| Day's Range | 0.9700 - 1.0900 |
| 52-Week Range | 0.2700 - 1.5500 |
| Beta | 0.55 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatm... [Read more]
Financial Performance
Financial StatementsNews
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condit...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
BALA CYNWYD, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ)
BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Why Werewolf Therapeutics stock exploded higher and what comes next?
Werewolf Therapeutics (HOWL) stock exploded higher on Friday morning after management said the company has agreed to a definitive all-stock merger with Ambros Therapeutics. The combined company will p...
Why Is Penny Stock Werewolf Therapeutics (HOWL) Up Today?
Werewolf Therapeutics stock was up 127.23% on Friday alongside news that the company will combine with Ambros Therapeutics in an all-stock deal.
Werewolf Therapeutics, Ambros Therapeutics to combine in all-stock transaction
Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focu...
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agr...
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
WATERTOWN, Mass., July 31, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of cond...
Werewolf Therapeutics Quarterly report: Q2 2026
Werewolf Therapeutics has published its Q2 2026 quarterly earnings report on July 31, 2026.
Werewolf Therapeutics Earnings release: Q2 2026
Werewolf Therapeutics released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condi...
Werewolf Therapeutics Quarterly report: Q1 2026
Werewolf Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Werewolf Therapeutics Earnings release: Q1 2026
Werewolf Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Werewolf Therapeutics hires Piper Sandler to assist in strategic evaluation
Werewolf Therapeutics (HOWL) announced that the company has engaged Piper Sandler & Co. to serve as exclusive financial advisor to assist in a strategic evaluation process. “The company does not…
Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c)
As of December 31, 2025, cash and cash equivalents were $57.1M, compared to $65.7M as of September 30, 2025. The company believes its cash and cash equivalents as of December…
Werewolf Therapeutics to explore range of strategic alternatives
07:07 EDT Werewolf Therapeutics (HOWL) to explore range of strategic alternatives
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
Werewolf Therapeutics Annual report: Q4 2025
Werewolf Therapeutics has published its Q4 2025 annual report on March 27, 2026.
Werewolf Therapeutics Earnings release: Q4 2025
Werewolf Therapeutics released its Q4 2025 earnings on March 27, 2026, summarizing the period's financial results.
Werewolf Therapeutics to explore strategic alternatives
Earlier this evening, Werewolf Therapeutics (HOWL) “announced that the company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to ma...
Werewolf Therapeutics trading resumes
16:30 EST Werewolf Therapeutics (HOWL) trading resumes
Werewolf Therapeutics trading halted, news pending
16:10 EST Werewolf Therapeutics (HOWL) trading halted, news pending
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of ther...
Werewolf Therapeutics announces 64% workforce reduction
In a regulatory filing, the company said, “On February 9, 2026, the board of directors of Werewolf Therapeutics (HOWL) approved a reduction in force, representing 64% of the company’s workforce.